Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers

S Preskorn, A Patroneva, H Silman… - Journal of clinical …, 2009 - journals.lww.com
Background: The goal of this study was to evaluate the impact of cytochrome P450 2D6
extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single …

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

…, Q Jiang, J Paul, AI Nichols, A Patroneva… - The Journal of clinical …, 2010 - psychiatrist.com
Objectives: To determine the relative efficacy and tolerability of venlafaxine in EM vs PM
patients with major depressive disorder (MDD). Method: Data from 4 double-blind, placebo-…

Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system

…, AI Nichols, J Paul, AL Patroneva… - Journal of Psychiatric …, 2008 - journals.lww.com
Background The cytochrome P450 2D6 (CYP2D6) enzyme is responsible for metabolizing
approximately 25% of pharmaceutical agents. Individuals with impaired CYP2D6 metabolism …

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects

A Patroneva, SM Connolly, P Fatato, R Pedersen… - Drug metabolism and …, 2008 - ASPET
A number of antidepressants inhibit the activity of the cytochrome P450 2D6 enzyme system,
which can lead to drug-drug interactions. Based on its metabolic profile, desvenlafaxine, …

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults

…, Q Jiang, S Ahmed, A Patroneva - The Journal of …, 2009 - Wiley Online Library
The potential for cytochrome P450 (CYP) 2D6 substrates to interact with desvenlafaxine (administered
as desvenlafaxine succinate) and paroxetine was evaluated. In an open‐label, …

Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004)

CR Chapple, A Patroneva, SR Raines - European urology, 2006 - Elsevier
OBJECTIVES: Improvements over existing treatment standards in overactive bladder (OAB)
may only be possible through the development of drugs acting via non-cholinergic pathways…

A multicenter, double-blind, randomized, placebo-controlled phase 3 trial to determine the efficacy and safety of ganaxolone as adjunctive therapy for adults with drug …

J Lappalainen, J Tsai, W Amerine, A Patroneva - 2017 - AAN Enterprises
Objective: To assess ganaxolone as adjunctive therapy in drug-resistant focal-onset
seizures Background: Ganaxolone is a synthetic analog of allopregnanolone and a positive …

Establishing the content validity of the Epworth Sleepiness Scale for Children and Adolescents in Prader-Willi syndrome

VP Patel, A Patroneva, DG Glaze… - Journal of Clinical …, 2022 - jcsm.aasm.org
Study Objectives: Excessive daytime sleepiness is common in Prader-Willi syndrome (PWS),
with prevalence ranging from 52% to 100%. The goal of this study was to establish the …

A multicenter, open-label trial of ganaxolone in children with PCDH19 epilepsy (P5. 236)

…, M Chez, J Sullivan, J Gecz, N Specchio, A Patroneva - 2017 - AAN Enterprises
… , Michael Chez, Joseph Sullivan, Jozef Gecz, Nicola Specchio, Albena PatronevaPatroneva
has received personal compensation for activities with Marinus as the Chief Medical Officer …

0615 Pitolisant in combination with other medications for the management of narcolepsy

K Doghramji, CW Davis, A Patroneva, JC Schwartz… - Sleep, 2019 - search.proquest.com
Methods An open-label, crossover study, conducted in 16 healthy males, evaluated
pharmacokinetic (PK) interactions of pitolisant (35.6 mg, single-dose) with sodium oxybate (4.5 g, …